NASDAQ, EXAS - Exact Sciences Cor

EXACT Sciences Corporation is an applied genomics company that develops  proprietary DNA-based technologies for use in the detection of cancer. We have  selected colorectal cancer as the first application of our technologies. We have  licensed certain of our technologies, on an exclusive basis through December  2010, to Laboratory Corporation of America? Holdings ("LabCorp?") in connection  with a commercial testing service that is marketed in the United States under  the name "PreGen-Plus?." PreGen-Plus, which is based on our Version 1  technology, is LabCorp's non-invasive stool-based DNA testing service for the  detection of colorectal cancer in the average-risk population. Royalties from  LabCorp's sales of PreGen-Plus, and other license fees from LabCorp, represent  our primary source of revenue.  Colorectal cancer is the second leading cause of cancer death in the U.S.  and the leading cause of cancer death among non-smokers.  ...

Sector:	Health Care
Industry:	Biotechnology: Commercial Physical & Biological Resarch
P/E Ratio:	N/A
PEG Ratio:	N/A
EPS:	N/A
DivYield:	N/A
PtB:	4.1986
PtS:	34.69
EBITDA:	N/A
Shares:	188.64M
Market Cap:	7.732B
52wk range:	39.97 - 72.83

216.73.216.221
United States